GMAB - Genmab down 2% as it drops enapotamab vedotin development for treatment of cancer patients

Genmab ([[GMAB]] -2.1%) after news that  it's discontinuing its Phase 2 study of enapotamab vedotin and dropping development as the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.“We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward. This decision will allow us to focus more of our resources and energy on other programs in our robust next-generation antibody therapeutics pipeline,” says Jan van de Winkel, Ph.D., Chief Executive Officer.

For further details see:

Genmab down 2% as it drops enapotamab vedotin, development for treatment of cancer patients